Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.31 |
| ▸ | STK10 | O94804 | 1/20 | 0.31 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7093047 | 1.00 | GSK3B (0.31) | GSK3BEGFRERBB2STK10SLK | |
| SCHEMBL7095029 | 0.86 | GABBR2 (0.34) | — | |
| SCHEMBL7095026 | 0.86 | GABBR2 (0.34) | — | |
| SCHEMBL7158271 | 0.80 | CA1 (0.44) | EGFRSTK10SLKCA1CA2 | |
| SCHEMBL7089049 | 0.78 | ERBB2 (0.43) | EGFRERBB2STK10SLK | |
| SCHEMBL7089048 | 0.78 | ERBB2 (0.43) | EGFRERBB2STK10SLK | |
| SCHEMBL7090186 | 0.69 | ERBB2 (0.38) | EGFRERBB2STK10SLK | |
| SCHEMBL7090188 | 0.69 | ERBB2 (0.38) | EGFRERBB2STK10SLK | |
| SCHEMBL7092131 | 0.67 | TTR (0.40) | CA1CA2 | |
| SCHEMBL7092128 | 0.67 | TTR (0.40) | CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030121113-A1 | Oxobenzofuranylide-dihydroindolone | NESVADBA PETER (CH) | 2003-07-03 | — | — | US | disclosed |
| US-6503937-B1 | Coloring agents for high molecular weight materials such as polymers | CIBA SPECIALTY CHEMICALS CORPORATION | 2003-01-07 | — | — | US | disclosed |
| EP-1123289-B1 | OXOBENZOFURANYLIDE-DIHYDROINDOLONES | CIBA SC HOLDING AG (CH) | 2002-11-27 | — | — | EP | disclosed |
| EP-1123289-A1 | OXOBENZOFURANYLIDE-DIHYDROINDOLONE | Ciba SC Holding AG (CH) | 2001-08-16 | — | — | EP | disclosed |
| WO-2000024736-A1 | OXOBENZOFURANYLIDE-DIHYDROINDOLONE | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2000-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030121113-A1 | Oxobenzofuranylide-dihydroindolone | CYP1B1, CYP1A1, ECI1 | GSK3B 3019/4885EGFR 4081/4885ERBB2 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.